Biomedical Engineering Reference
In-Depth Information
treatment for metastatic breast cancer.
J Clin Oncol
, 2008.
26
(34):
5544-5552.
97. Geyer, C.E.,
, Lapatinib plus capecitabine for HER2-positive
advanced breast cancer.
et al.
N Engl J Med
, 2006.
355
(26): 2733-2743.
98. Gomez, H.L.,
, Efficacy and safety of lapatinib as first-line therapy
for ErbB2-amplified locally advanced or metastatic breast cancer.
et al.
J Clin
Oncol
, 2008.
26
(18): 2999-3005.
99. Johnston, S.,
, Lapatinib combined with letrozole versus letrozole
and placebo as first-line therapy for postmenopausal hormone
receptor-positive metastatic breast cancer.
et al.
J Clin Oncol
, 2009.
27
(33):
5538-5546.
100. Johnston, S.,
, Phase II study of predictive biomarker profiles for
response targeting human epidermal growth factor receptor 2 (HER-2)
in advanced inflammatory breast cancer with lapatinib monotherapy.
et al.
J
Clin Oncol
, 2008.
26
(7): 1066-1072.
101. Schwartzberg, L.S.,
, Lapatinib plus letrozole as first-line therapy
for HER-2+ hormone receptor-positive metastatic breast cancer.
Oncologist
et al.
, 2010.
15
(2): 122-129.
102. Toi, M.,
, Lapatinib monotherapy in patients with relapsed,
advanced, or metastatic breast cancer: efficacy, safety, and biomarker
results from Japanese patients phase II studies.
et al.
Br J Cancer
, 2009.
(10): 1676-1682.
103. Press, M.F.,
101
, HER-2 gene amplification, HER-2 and epidermal
growth factor receptor mRNA and protein expression, and lapatinib
efficacy in women with metastatic breast cancer.
et al.
Clin Cancer Res
, 2008.
(23): 7861-7870.
104. Agus, D.B.,
14
, Targeting ligand-activated ErbB2 signaling inhibits
breast and prostate tumor growth.
et al.
Cancer Cell
, 2002.
2
(2): 127-137.
105. Franklin, M.C.,
, Insights into ErbB signaling from the structure of
the ErbB2-pertuzumab complex.
et al.
Cancer Cell
, 2004.
5
(4): 317-328.
106. Jackson, J.G.,
, Blockade of epidermal growth factor- or heregulin-
dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody
2C4 has divergent downstream signaling and growth effects.
et al.
Cancer
Res
, 2004.
64
(7): 2601-2609.
107. Baselga, J.,
, Phase II trial of pertuzumab and trastuzumab in
patients with human epidermal growth factor receptor 2-positive
metastatic breast cancer that progressed during prior trastuzumab
therapy.
et al.
J Clin Oncol
, 2010.
28
(7): 1138-1144.
